Brainstorm Cell Therapeutics (BCLI) COO Purchases $18,000.00 in Stock
Brainstorm Cell Therapeutics (NASDAQ:BCLI) COO Ralph Dr. Kern purchased 5,000 shares of Brainstorm Cell Therapeutics stock in a transaction that occurred on Thursday, March 15th. The shares were acquired at an average price of $3.60 per share, with a total value of $18,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link.
Shares of Brainstorm Cell Therapeutics (NASDAQ BCLI) traded up $0.09 during trading hours on Friday, hitting $3.33. The stock had a trading volume of 20,780 shares, compared to its average volume of 60,491. Brainstorm Cell Therapeutics has a 12 month low of $2.88 and a 12 month high of $5.18. The company has a market capitalization of $61.42, a PE ratio of -12.35 and a beta of 1.95.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings data on Thursday, March 8th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.11. research analysts expect that Brainstorm Cell Therapeutics will post -0.66 earnings per share for the current year.
BCLI has been the subject of a number of research analyst reports. Maxim Group set a $9.00 price objective on Brainstorm Cell Therapeutics and gave the stock a “buy” rating in a report on Wednesday, December 27th. ValuEngine cut Brainstorm Cell Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, December 21st.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.watchlistnews.com/brainstorm-cell-therapeutics-bcli-coo-purchases-18000-00-in-stock/1961204.html.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc, a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd.
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.